At the center of deployment is mlHealth360’s proprietary Scaida AI platform, designed to detect and triage abnormalities in CT scans
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The results were consistent across both the 10 mg and 40 mg treatment arms
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
Subscribe To Our Newsletter & Stay Updated
